SKP
PFE icon

Sanborn Kilcollin Partners’s Pfizer PFE Stock Holding History

Sanborn Kilcollin Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$8.68M Sell
309,551
-161,267
-34% -$4.53M 6.07% 8
2014
Q2 		$13.3M Buy
470,818
+3,797
+0.8% +$108K 6.11% 6
2014
Q1 		$14.2M Buy
467,021
+22,454
+5% +$669K 7.18% 6
2013
Q4 		$12.9M Sell
444,567
-27,865
-6% -$811K 6.73% 6
2013
Q3 		$12.9M Buy
472,432
+38,139
+9% +$1.04M 6.79% 6
2013
Q2 		$11.5M Buy
+434,293
New +$12M 7.02% 4

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sanborn Kilcollin Partners's PFE Position: Q3 2014 in Review

Sanborn Kilcollin Partners reduced its Pfizer (PFE) stake by 34% in Q3 2014, selling an estimated $4.53M and leaving 309,551 shares worth $8.68M. The position accounts for 6.07% of the portfolio, ranked #8.

Sanborn Kilcollin Partners first reported a position in PFE in Q2 2013 and has held it in 6 quarters since. The position peaked at $14.2M in Q1 2014. 1,741 funds tracked by Wall St. Rank hold PFE as of Q3 2014.

  • Sanborn Kilcollin Partners held 309,551 shares of Pfizer worth $8.68M as of Q3 2014.
  • Sanborn Kilcollin Partners sold 161,267 Pfizer shares in Q3 2014, an estimated $4.53M.
  • Pfizer made up 6.07% of Sanborn Kilcollin Partners's portfolio in Q3 2014, its #8 holding.
  • Sanborn Kilcollin Partners first reported a position in Pfizer in Q2 2013 and has held it in 6 quarters since.
  • Sanborn Kilcollin Partners's Pfizer position peaked at $14.2M in Q1 2014.
  • 1,741 funds tracked by Wall St. Rank held Pfizer as of Q3 2014.

Based on Sanborn Kilcollin Partners's 13F filing for Q3 2014, filed 13 Nov 2014.